Dr. Bordelon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1001 12th Ave
Suite 200
Fort Worth, TX 76104Phone+1 817-850-5000Fax+1 817-850-2065
Education & Training
- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1971 - 1973
- Louisiana State University (Shreveport)Internship, Transitional Year, 1968 - 1969
- Louisiana State University School of Medicine in New OrleansClass of 1968
Certifications & Licensure
- TX State Medical License Active through 2013
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Top MD Consumers Checkbook
Publications & Presentations
PubMed
- 395 citationsDocetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research...Stephen E. Jones, Frankie A. Holmes, Joyce O'Shaughnessy, Joanne L. Blum, Svetislava J. Vukelja
Journal of Clinical Oncology. 2009-03-10 - 57 citationsComparison of Menopausal Symptoms During the First Year of Adjuvant Therapy With Either Exemestane or Tamoxifen in Early Breast Cancer: Report of a Tamoxifen Exemestan...Stephen E. Jones, J. Cantrell, Svetislava J. Vukelja, John Pippen, Joyce O'Shaughnessy
Journal of Clinical Oncology. 2007-10-20 - 375 citationsPhase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast CancerStephen E. Jones, Michael Savin, Frankie A. Holmes, Joyce O'Shaughnessy, Joanne L. Blum
Journal of Clinical Oncology. 2006-12-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: